Can-Fite BioPharma Ltd. Quarterly Deferred Tax Assets, Operating Loss Carryforwards in USD from Q4 2018 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary
Can-Fite BioPharma Ltd. quarterly Deferred Tax Assets, Operating Loss Carryforwards history and growth rate from Q4 2018 to Q4 2023.
  • Can-Fite BioPharma Ltd. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending December 31, 2023 was $25.6M, a 1.87% increase year-over-year.
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $25.6M +$469K +1.87% Dec 31, 2023 20-F 2024-03-28
Q4 2022 $25.1M -$1.21M -4.6% Dec 31, 2022 20-F 2024-03-28
Q4 2021 $26.3M -$5.96M -18.5% Dec 31, 2021 20-F 2023-03-30
Q4 2020 $32.3M +$5.02M +18.4% Dec 31, 2020 20-F 2022-03-24
Q4 2019 $27.3M +$4.36M +19% Dec 31, 2019 20-F 2021-03-25
Q4 2018 $22.9M Dec 31, 2018 6-K 2020-06-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.